New Target For Treating Diabetic Kidney Disease, The Leading Cause Of Kidney Failure

Authors: Medical News Today

Main Category: Diabetes
Also Included In: Urology / Nephrology
Article Date: 22 Oct 2012 - 0:00 PDT

Current ratings for:
New Target For Treating Diabetic Kidney Disease, The Leading Cause Of Kidney Failure


Patient / Public:5 stars

5 (1 votes)

Healthcare Prof:New Target For Treating Diabetic Kidney Disease, The Leading Cause Of Kidney Failure

5 (3 votes)


About 20%-30% of patients with diabetes develop evidence of diabetic nephropathy.

Researchers have discovered a new therapeutic target for diabetic nephropathy, the leading cause of kidney failure. The findings, appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN), could help protect the kidney health of individuals with diabetes.

While it's unclear precisely how diabetic nephropathy - kidney disease or damage that occurs in people with diabetes - develops, inflammation is likely involved. One particular inflammatory molecule, osteopontin, seems to play a prominent role, making it a potential target for future therapies.

In an attempt to inhibit osteopontin expression, Daisuke Ogawa, MD, PhD (Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, in Japan) and his colleagues tried activating a receptor that blocks the expression of genes involved in inflammation. This receptor, liver x receptor (LXR), can be activated with a drug named T0901317.

When diabetic mice with kidney damage were given T0901317, the animals' kidneys became healthier and functioned better. Also, the T0901317 treatment markedly decreased the expression of osteoponin and other inflammatory molecules in the kidneys. Laboratory experiments with kidney cells revealed that high sugar concentrations - like those seen in the blood of diabetics - increased osteopontin expression, which could be inhibited with T0901317.

"These observations support an important role for LXR agonists in suppressing the inflammatory responses in diabetic kidneys and preventing the development of nephropathy," said Dr. Ogawa.

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our diabetes section for the latest news on this subject.
Study co-authors include Hiromi Tachibana, Yuichi Matsushita, Dennis Bruemmer, Jun Wada, Sanae Teshigawara, Jun Eguchi, Chikage Sato-Horiguchi, Haruhito Adam Uchida, Kenichi Shikata, and Hirofumi Makino.
Disclosures: The authors reported no financial disclosures.
The article, entitled "Activation of Liver X Receptor Inhibits Osteopontin and Ameliorates Diabetic Nephropathy," appears online at http://jasn.asnjournals.org/, doi: 10.1681/ASN.2012010022.
American Society of Nephrology
Please use one of the following formats to cite this article in your essay, paper or report:

MLA

n.p. "New Target For Treating Diabetic Kidney Disease, The Leading Cause Of Kidney Failure." Medical News Today. MediLexicon, Intl., 22 Oct. 2012. Web.
3 Nov. 2012. <http://www.medicalnewstoday.com/releases/251728.php>


APA

Please note: If no author information is provided, the source is cited instead.


Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

Read more http://www.medicalnewstoday.com/releases/251728.php

PUA Social Network

Twitter Facebook

Contact us

The Philippine Urological Association,Inc
3rd floor. PCS Bldg., 992 EDSA, Quezon City,
Metro Manila, PHILIPPINES 1105
View Map

+632-9256740 
+632-4544439
+63917-5244456

eMail us